证券代码：300584 证券简称：海辰药业 公告编号：2023-025 南京海辰药业股份有限公司 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《公司章程》的有关规定。 二、董事会会议审议情况 会议审议并通过如下议案： 1、审议通过《2023 年半年度报告全文及摘要的议案》 第四届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会由董事长曹于平先生召集，会议通知于 2023 年 8 月 11 日电 话、电子邮件、专人送达等形式送达至各位董事，董事会会议通知中包括会议的 相关材料，同时列明了会议的召开时间、地点、内容和方式。 2、本次董事会于 2023 年 8 月 22 日在公司会议中心三楼会议室召开，本次 会议采取现场结合通讯表决方式召开。 3、本次董事会应出席 7 人，实际出席会议人数为 7 人，其中毛凌霄以通讯 表决方式参会。 4、本次董事会由董事长曹于平先生主持，公司高级管理人员、证券部工作 人员列席了会议。 经审核，董事会认为编制和审核南京海辰药业股份有限公司 ...

证券代码：300584 证券简称：海辰药业 公告编号：2023-026 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、本次监事会由监事会主席罗艳女士召集，会议通知于 2023 年 8 月 11 日 电话、电子邮件、专人送达等形式送达至各位董事，董事会会议通知中包括会议 的相关材料，同时列明了会议的召开时间、地点、内容和方式。 南京海辰药业股份有限公司 第四届监事会第九次会议决议公告 2、本次监事会于 2023 年 8 月 22 日在公司会议中心三楼会议室召开，本次 会议采取现场结合通讯表决方式召开。 3、本次监事会应出席 3 人，实际出席会议人数为 3 人，其中褚源红以通讯 表决方式参会。 4、本次监事会由监事会主席罗艳女士主持。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《公司章程》的有关规定。 二、监事会会议审议情况 会议审议并通过如下议案： 1、审议通过《2023 年半年度报告全文及摘要的议案》 监事会审核后认为：公司董事会对《2023 年半年度报告全文》的编制和审核 程序符合法律、行政法规 ...

证券代码：300584 证券简称：海辰药业 南京海辰药业股份有限公司 2022 年度网上业绩说明会 暨投资者关系活动记录表 编号：2023-001 | 投资者关系活 | □特定对象调研 □分析师会议 | | --- | --- | | 动类别 | □媒体采访 √业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 □其他 （请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | 通过同花顺上市公司路演平台（https：//board.10jqka.com.cn/ir）参 | | | 加公司 2022 年度业绩说明会的投资者 | | 交流时间 | 年 月 日下午 至 2023 5 5 15：00 17：00 | | 地点 | 同花顺上市公司路演平台（https：//board.10jqka.com.cn/ir） | | | 公司董事长、总经理：曹于平先生 | | 上市公司参会 | 独立董事：赵鸣先生 | | 人员姓名 | 董事会秘书、副总经理：王立先生 | | | 财务总监：陈建仁先生 | | | 2022 年度网上业绩说明会互动交流主要问答如下： | | | 1、请问对公司股票的走 ...

Financial Performance - In 2022, the company achieved operating revenue of 526 million RMB, a year-on-year decrease of 8.97%[5] - The net profit attributable to shareholders was 32.45 million RMB, down 88.65% year-on-year, while the net profit excluding non-recurring gains and losses increased by 30.79% to 31.46 million RMB[5] - The significant decline in net profit was primarily due to a fair value change gain of 306.13 million RMB recognized in 2021, which contributed to a net profit of 260.21 million RMB that year[5] - The cash flow from operating activities was negative at -¥5,819,338.75, a decline of 109.71% from ¥59,940,771.89 in 2021[23] - The basic earnings per share dropped to ¥0.2704, down 88.65% from ¥2.3823 in 2021[23] - Total assets at the end of 2022 were ¥1,293,945,410.29, a slight decrease of 0.62% from ¥1,302,008,303.05 in 2021[23] - The company reported a total distributable profit of RMB 607,536,449.71 for the year, but did not propose any cash dividend distribution for 2022[154] Dividend and Shareholder Engagement - The company plans to distribute no cash dividends and no bonus shares for the year, with a capital reserve transfer of 0 shares for every 10 shares held[6] - The annual shareholders meeting had a participation rate of 62.17% on May 16, 2022[117] - The first extraordinary shareholders meeting had a participation rate of 62.04% on June 27, 2022[117] - The second extraordinary shareholders meeting also had a participation rate of 62.04% on July 15, 2022[118] - The company is committed to maintaining a high level of shareholder engagement as evidenced by the participation rates in meetings[117][118] Market and Product Development - The company aims to improve operational performance in 2023, despite the challenges faced in the previous year[5] - The company’s future outlook includes potential market expansion and new product development strategies[5] - The company is actively developing new products, with plans to submit consistency evaluation applications for several drugs in 2023, including Sodium Thiosulfate and Acetylcysteine injection[54] - The company has established a complete procurement, production, and sales system, ensuring stable supply and quality control in compliance with GMP standards[43][45] - The company is expanding its marketing network by developing partnerships with chain pharmacies and online channels, creating a multi-channel marketing strategy[49] Research and Development - The company has a strong R&D capability with over 60 dedicated personnel and has undertaken more than 20 national and provincial-level technology projects, enhancing its innovation in high-end generic and innovative drug development[46][47] - Research and development (R&D) investment amounted to ¥34,884,000.84 in 2022, representing 6.63% of operating revenue, a decrease from 10.01% in 2021[82] - The company has made significant progress in R&D projects, with multiple products nearing production approval, indicating a strong pipeline for future growth[80] - The company is focused on establishing quality standards for new raw materials and formulations, which is expected to enrich its product offerings[81] Regulatory Compliance and Risk Management - The management highlighted risks including changes in industry policies, new drug development risks, and a decline in market share for the main product Torasemide[5] - The company is committed to maintaining compliance with GMP standards and regulatory requirements from NMPA and FDA[17] - The company is aware of potential investment risks related to its new projects and will monitor market conditions closely[106] - The company emphasizes the importance of effective management and coordination as it expands its operations and increases the number of subsidiaries[106] Environmental Responsibility - The company has established comprehensive environmental management systems and complies with national and local environmental regulations[167] - The wastewater discharge meets the standards set by GB/T31962-2015 and DB32/939-2020, ensuring compliance with environmental laws[168] - The company has implemented measures to control emissions of volatile organic compounds (VOCs), with a total discharge of 3.42 tons, which is within the regulatory limits[169] - The company invested 1.7888 million yuan in environmental governance and protection during the reporting period[177] Governance and Management - The company has established a comprehensive governance structure, including a board of directors and supervisory board, to ensure effective decision-making and oversight[111] - The company has a performance evaluation and incentive mechanism for directors and senior management linked to company performance[113] - The company has implemented a profit distribution plan that considers both short-term and long-term shareholder interests[179] - The company has a structured governance framework, including a board of directors and an audit committee, to ensure compliance with laws and regulations[159] Employee Engagement and Welfare - Employee welfare initiatives included organizing multiple health check-ups and enhancing facilities such as a mother-baby room and fitness center[180] - The company organized 213 training sessions with a total of 1,084 training hours during the reporting period, aiming to enhance employee skills and company cohesion[149] - The total number of employees at the end of the reporting period is 549, with 437 in the parent company and 112 in major subsidiaries[147] - The company has a robust governance structure that includes a shareholders' meeting, board of directors, and supervisory board to protect minority shareholders' rights[179]

Financial Performance - The company's revenue for Q1 2023 was ¥117,201,090.18, a decrease of 22.18% compared to ¥150,605,102.60 in the same period last year[5] - Net profit attributable to shareholders was ¥12,213,813.89, down 3.23% from ¥12,620,961.53 year-on-year[5] - The company's basic and diluted earnings per share were both ¥0.1018, a decrease of 3.23% compared to ¥0.1052 in the same period last year[5] - Total operating revenue for Q1 2023 was ¥117,201,090.18, a decrease of 22.2% compared to ¥150,605,102.60 in Q1 2022[21] - Net profit for Q1 2023 was ¥12,213,813.89, slightly down from ¥12,448,499.59 in the same period last year, a decrease of 1.9%[22] Cash Flow - The net cash flow from operating activities improved significantly to ¥29,506,108.77, a 173.51% increase from a negative cash flow of -¥40,136,476.98 in the previous year[5] - Operating cash flow for Q1 2023 was ¥29,506,108.77, a significant improvement from a negative cash flow of ¥40,136,476.98 in Q1 2022[24] - The net cash flow from financing activities was ¥21,493,951.38, a 235.30% increase compared to -¥15,886,571.19 in the same period last year[9] - The net cash flow from investment activities was -53,605,687.16 CNY, compared to a net cash inflow of 23,247,822.60 CNY in the previous period[25] - Cash inflow from financing activities was 49,000,000.00 CNY, while cash outflow was 27,506,048.62 CNY, resulting in a net cash flow of 21,493,951.38 CNY[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,333,752,341.08, reflecting a 3.08% increase from ¥1,293,945,410.29 at the end of the previous year[5] - The total assets of the company as of March 31, 2023, were approximately 1.33 billion RMB, an increase from 1.29 billion RMB at the beginning of the year[18] - The company’s total liabilities increased to approximately 337.83 million RMB from 317.05 million RMB at the beginning of the year[18] - The total liabilities increased to ¥370,907,991.94 from ¥343,379,013.86, an increase of 8.1%[22] Equity - The total equity attributable to shareholders increased by 1.29% to ¥962,844,349.14 from ¥950,566,396.43 at the end of the previous year[5] - The total equity attributable to shareholders of the parent company rose to ¥962,844,349.14 from ¥950,566,396.43, an increase of 1.3%[22] Research and Development - Research and development expenses decreased by 37.09% to ¥3,013,143.82 from ¥4,789,264.33 year-on-year[9] - Research and development expenses were ¥3,013,143.82, down 37.5% from ¥4,789,264.33 in the previous year[21] Sales Performance - Sales of the product "Injectable Lantidilol 50mg" reached 340,600 units, with a sales amount of 47.78 million RMB, representing an 88% increase in volume and 89% increase in sales amount year-over-year[15] - Sales of "Rivaroxaban Tablets 15mg*7" decreased by 10% in both volume and sales amount, totaling 217,300 boxes and 13.36 million RMB[15] Shareholder Information - The largest shareholder, Mr. Cao Yuping, holds 42.08% of the shares, while the second-largest shareholder, Ms. Jiang Xiaoqin, holds 9.98%[11] Other Financial Metrics - The net profit excluding non-recurring gains and losses increased by 4.08% year-over-year to 12.57 million RMB[14] - Accounts receivable decreased from 185.38 million RMB at the beginning of the year to 167.74 million RMB[17] - The company’s cash and cash equivalents at the end of Q1 2023 were approximately 92.47 million RMB, down from 95.07 million RMB at the beginning of the year[17] - The total cash and cash equivalents at the end of the period amounted to 92,465,697.80 CNY, down from 113,795,568.27 CNY at the beginning of the period[25] - The company reported a decrease in cash and cash equivalents of -2,602,425.67 CNY for the quarter[25] Audit Information - The company did not conduct an audit for the first quarter report[26]

证券代码：300584 证券简称：海辰药业 公告编号：2023-014 南京海辰药业股份有限公司 为提高交流效率，公司现提前向投资者征集相关问题，广泛听取投资者的意 见和建议。投资者可于 2023 年 4 月 28 日（星期五）16:00 时前将有关问题通过 电子邮件的形式发送至公司投资者关系邮箱（ir@hicin.cn）。欢迎广大投资者积 极参与。 特此公告。 南京海辰药业股份有限公司董事会 2023 年 4 月 24 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 南京海辰药业股份有限公司（以下简称"公司"）于 2023 年 4 月 24 日在 巨潮资讯网（www.cnino.com.cn）披露了 2022 年年度报告及摘要。为方便广大 投资者进一步了解公司 2022 年年度报告及经营情况，公司定于 2023 年 5 月 5 日（星期五）下午 15：00-17：00 举行 2022 年度业绩说明会。本次说明会将采 用网络远程方式举行，投资者可登录同花顺上市公司路演平台 （https://board.10jqka.com.cn/ir）或者同花顺 App ...

证券代码：300584 证券简称：海辰药业 编号：2017-001 | --- | --- | --- | |----------------|---------------|---------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 1 华泰证券 | 代雯 | | 人员姓名 | 2 东兴证券 | 张金洋 | | | 3 平安证券 | 叶寅 | | | 4 中泰证券 | 江琦 | | | 5 广发证券 | 冯鹏 | | | 6 方正证券 | 张一驰 | | | 7 天风证券 | 廖庆阳 | | | 8 中信证券 | 刘泽序 | | | 9 中信证券 | 李冬 | | | 10 华泰证券 | 李沄 | | | 11 中泰证券 | 祝嘉琦 | | | 12 鹏华基金 | 桑翔宇 | 南京海辰药业股份有限公司投资者关系活动记录表 ...

证券代码：300584 证券简称：海辰药业 南京海辰药业股份有限公司投资者关系活动记录表 编号：2017-002 | --- | --- | |----------------|---------------------------------| | | | | 投资者关系活动 | 特定对象调研 □分析师会议 | | 类别 | 媒体采访 □业绩说明会 | | | 新闻发布会 □路演活动 | | | | | | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 钟田甜、周洁、赵冰 | | 人员姓名 | 凯思博 黄卉 | | | 富国基金 钱伟华 | | | 万家基金 叶勇 | | | 熊宏婷 | | | 禾其投资 曹洋 | | | 景林资产 高云程 | | | 传家堡 黄梓铭 | | | 胡瑞雯 | | | 10 HARDING LOEVNER 李靖毅 | | | 深交所 邵元辰 | | 时间 | 月 6 日上午 8:40-9:30 | | --- | --- | --- | |-------------------------|----------------------------------- ...

证券代码：300584 证券简称：海辰药业 南京海辰药业股份有限公司投资者关系活动记录表 编号：2019-001 | --- | --- | --- | --- | |--------------|----------------------------|-------------------------------------------|---------------------------------| | | | | | | 投资者关系活 | √ | 特定对象调研 □分析师会议 | | | 动类别 | □ | 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | | □ 现场参观 | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | 1. 光大证券 林小伟 | | | | 及人员姓名 | 2. 光大证券 宋硕 | | | | | 3. 国泰君安 孙明达 | | | | | 4. 千合资本 殷萌 | | | | | 5. 东方资管 解婕 | | | | | 6. 紫金财险 吴磊磊 | | | | | 7. 紫金财险 周路 | | | | 交流时间 | 20 ...

证券代码：300584 证券简称：海辰药业 南京海辰药业股份有限公司投资者关系活动记录表 编号：2018-003 | --- | --- | --- | --- | |----------------|-----------------------------------|-------------------|---------------------------------| | | | | | | 投资者关系活动 | √ 特定对象调研 □分析师会议 | | | | 类别 | □ 媒体采访 □业绩说明会 | | | | | □ 新闻发布会 □路演活动 | | | | | □ 现场参观 | | | | | □ 其他 （请文字说明其他活动内容） | | | | 参与单位名称及 | 1 、兴业证券 高级研究员 孙媛媛 | | | | 人员姓名 | 2 、兴业证券 研究员 赵垒 | | | | | 3 、华富基金 基金经理 翁海波 | | | | | 4 、广发证券 高级经理 姚凯飞 | | | | 时间 | 2018 年 6 月 4 | 日下午 | 14:00-16:00 | | 地点 | 南京海辰药业股份有限 ...